GHP Q4 2022 has the potential to eradicate the suffering caused by reflux, without the side effects typically associated with surgical interventions. Indeed, traditional surgical interventions are only considered in the most extreme cases due to the prevalence of disturbing side effects associated with these traditional surgical options. The RefluxStop procedure is currently being performed in Germany, Switzerland, Austria and the UK at several key hospitals such as University Hospital AKH Vienna, one of Europe’s largest hospitals and Klinikum Friedrichshafen, one of the most prominent anti-reflux centres in Germany. With such incredible support for this new technology in Europe, it’s of little surprise that the Implantica team is in the process of applying for approval for use in the US. The FDA has agreed to a PMA application for RefluxStop based solely on existing European clinical data, which would allow the firm to enter the US market without premarket US clinical trials, using instead safety and efficacy data from ongoing European clinical investigations. In many ways, RefluxStop showcases the effectiveness of Implantica’s product selection and design process. RefluxStop not only demonstrated outstanding clinical results so far, but also meets an enormous unmet need. RefluxStop could help millions of patients around the world, as well as save immense resources within healthcare systems as evidenced by a recently completed health economic analysis by the York Health Economics Consortium of University of York. RefluxStopTM validates Implantica’s potential, which is second to none. This incredible product is only the beginning of the product pipeline. While working on the commercialisation of RefluxStop in Europe, the team is also developing three additional implants in the form of UriControl, UriRestore and AppetiteControl. These devices utilise the team’s innovative Wireless Energising and eHealth platforms, each of them having the potential to revolutionise their respective treatment areas. UriControl is designed as a wirelessly energised remote-controlled artificial urinary sphincter for the over 200 million people suffering from urinary incontinence. UriRestore in turn is designed for people who lose their ability to empty their urinary bladder, oftentimes due to spinal cord injuries or multiple sclerosis. The device offered by Implantica will allow patients to empty their urinary bladders using a remote control. For the 100 million people worldwide, who are not able to urinate and depend on catheterisation, this technology would be a huge relief and life changing for these patients. AppetiteControl is designed as a revolutionary treatment for obesity by controlling appetite. This device is supported by a novel food sensor, which monitors a patient’s eating behaviour. When eating and as the stomach becomes full, it stretches and distends the stomach wall. This activates stretch receptors, which send a signal to the brain and results in a feeling of satiety. AppetiteControl uses this natural mechanism of action to create a feeling of fullness by stretching the stomach wall. The stretching is activated by reaching a pre-programmed food intake, programmed individually for each meal. The food intake allowances can be changed remotely on distance by the healthcare provider using the eHealth platform. The team’s incredible IP portfolio showcases the potential for some of the biggest innovations made in the medical industry in recent years. From this amazing resource, a range of lifechanging products are being prepared for use in the market at large. We celebrate the team’s success with this Most Innovative MedTech Company - Central Europe Award. Congratulations Implantica! Company: Implantica Name: Nicole Pehrsson Email: [email protected]
RkJQdWJsaXNoZXIy MTQxNTg3MQ==